title: Assessment of new vaccines in immunization programs.
abstract: Preventive technologies have had major impacts on disease incidence, mortality and costs. New preventive technologies are likely to further improve the public health in a cost-effective manner and require careful assessment to ensure their appropriate use. As in the appraisal of curative and diagnostic health technologies, a full evaluation of preventive technologies requires study of the epidemiologic, economic, ethical, social and legal issues related to their use. The appraisal of three new vaccines--for Hemophilus influenzae Type B, hepatitis B virus and varicella zoster--provides an illustration of the assessment of new preventive technologies.
mesh_terms: D000328:Adult; D016667:Bacterial Capsules; D001428:Bacterial Vaccines; D002644:Chickenpox / Q000191:economics / Q000517:prevention & control; D019433:Chickenpox Vaccine; D002648:Child; D003362:Cost-Benefit Analysis; D006192:Haemophilus Infections / Q000191:economics / Q000517:prevention & control; D018073:Haemophilus Vaccines; D006193:Haemophilus influenzae / Q000276:immunology; D006291:Health Policy; D006509:Hepatitis B / Q000453:epidemiology / Q000517:prevention & control; D017325:Hepatitis B Vaccines; D006801:Humans; D007223:Infant; D011135:Polysaccharides, Bacterial; D014611:Vaccination / Q000191:economics; D014761:Viral Hepatitis Vaccines; D014765:Viral Vaccines
chemical_list: D001428:Bacterial Vaccines; D019433:Chickenpox Vaccine; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D017325:Hepatitis B Vaccines; D011135:Polysaccharides, Bacterial; D014761:Viral Hepatitis Vaccines; D014765:Viral Vaccines